01:46 , May 5, 2018 |  BioCentury  |  Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
02:00 , Oct 28, 2017 |  BioCentury  |  Strategy

Biogen doubles down

Shares of Biogen Inc. were buffeted last week by a pair of poorly understood moves intended to improve the big biotech’s share of profits for aducanumab, along with lower than expected revenues for newly launched...
23:53 , Jul 25, 2017 |  BC Extra  |  Company News

Spinraza sales drive Biogen's guidance bump

Biogen Inc. (NASDAQ:BIIB) reported 2Q17 earnings, raised its full-year revenue guidance for 2017 and laid out a five-part growth strategy that emphasizes multiple sclerosis, spinal muscular atrophy (SMA) and neuroscience. The company said faster-than-expected uptake of...
21:08 , May 25, 2017 |  BC Extra  |  Company News

Merck obtains rights to Teijin's tau candidate

Teijin Pharma Ltd. (Tokyo, Japan) granted Merck & Co. Inc. (NYSE:MRK) exclusive rights to an undisclosed preclinical antibody targeting microtubule-associated protein tau (tau; MAPT; FTDP-17). Merck plans to develop the candidate to treat Alzheimer’s disease. Teijin...
16:33 , Apr 14, 2017 |  BC Week In Review  |  Company News

BMS, Biogen deal

Bristol-Myers granted Biogen exclusive rights to BMS-986168. The mAb targeting microtubule-associated protein tau (tau; MAPT; FTDP-17) has completed a Phase Ib trial to treat progressive supranuclear palsy (PSP). Biogen said it intends to start Phase...
19:32 , Apr 13, 2017 |  BC Extra  |  Company News

BMS out-licenses programs to Biogen, Roche

Bristol-Myers Squibb Co. (NYSE:BMY) said Thursday it out-licensed a pair of programs to Biogen Inc. (NASDAQ:BIIB) and Roche (SIX:ROG; OTCQX:RHHBY). Spokesperson Chrissy Trank told BioCentury the deals end BMS's clinical development of therapies for genetically...
07:00 , Jul 28, 2016 |  BC Innovations  |  Targets & Mechanisms

Effectorless efficacy

In a finding that might solve the problem of dose-limiting side effects for using antibodies in CNS disorders, a Genentech-led team has engineered an anti-tau antibody for Alzheimer's disease that binds its target in the...
00:59 , Oct 15, 2015 |  BC Extra  |  Clinical News

CurePSP program recruits patients for AbbVie, BMS trials

Non-profit CurePSP (Timonium, Md.) said it formed the Patient Engagement Program to assist in patient recruitment for clinical trials to treat degenerative brain diseases including progressive supranuclear palsy (PSP). CurePSP said it agreed with AbbVie...
07:00 , May 5, 2014 |  BC Week In Review  |  Company News

iPierian, Bristol-Myers deal

Bristol-Myers Squibb acquired neurology play iPierian for $175 million in cash up front and up to $550 million in milestones, plus royalties. iPierian's IPN007 is a preclinical humanized mAb targeting microtubule-associated protein tau...
00:43 , Apr 30, 2014 |  BC Extra  |  Top Story

BMS acquires iPierian, reports 1Q14 earnings

Bristol-Myers Squibb Co. (NYSE:BMY) reported mixed 1Q14 financial results on Tuesday and separately said it acquired neurology play iPierian Inc. (South San Francisco, Calif.) for $175 million in cash up front and up to $550...